Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

Mise à jour : Il y a 4 ans
Référence : NCT01365455

Femme et Homme

Extrait

This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.


Critère d'inclusion

  • Moderate to severe plaque-type psoriasis


Liens